Top

Published in:

Open Access 01-12-2013 | Research

Eosinophils in human oral squamous carcinoma; role of prostaglandin D2

Authors: Francis Davoine, Adrian Sim, Charlie Tang, Sibina Fisher, Caroline Ethier, Lakshmi Puttagunta, Yingqi Wu, W Tim McGaw, Donald Yu, Lisa Cameron, Darryl J Adamko, Redwan Moqbel

Published in: Journal of Inflammation | Issue 1/2013

Abstract

Eosinophils are often predominant inflammatory leukocytes infiltrating oral squamous carcinoma (OSC) sites. Prostaglandins are secreted by oral carcinomas and may be involved in eosinophil infiltration. The objective of this study was to determine the factors contributing to eosinophil migration and potential anti-neoplastic effects on OSC. Eosinophil degranulation was evaluated by measuring release of eosinophil peroxidase (EPO). Eosinophil chemotaxis towards OSC cells was assessed using artificial basement membrane. Eosinophil infiltration was prominent within the tissue surrounding the OSC tumor mass. We observed growth inhibition of the OSC cell line, SCC-9, during co-culture with human eosinophils, in vitro, which correlated with EPO activity that possesses growth inhibitory activity. The PGD₂ synthase inhibitor, HQL-79, abrogated migration towards SCC-9. Our data suggest that OSC-derived PGD₂ may play an important role via CRTH2 (the PGD₂ receptor on eosinophils) in eosinophil recruitment and subsequent anti-tumor activity through the action of eosinophil cationic proteins.

Available only for authorised users

Adamko DJ, Odemuyiwa SO, Vethanayagam D, Moqbel R: The rise of the phoenix: the expanding role of the eosinophil in health and disease. Allergy. 2005, 60: 13-22. 10.1111/j.1398-9995.2005.00676.x.PubMedCrossRef

Samoszuk M: Eosinophils and human cancer. Histol Histopathol. 1997, 12: 807-812.PubMed

Falconieri G, Luna MA, Pizzolitto S, DeMaglio G, Angione V, Rocco M: Eosinophil-rich squamous carcinoma of the oral cavity: a study of 13 cases and delineation of a possible new microscopic entity. Ann Diagn Pathol. 2008, 12: 322-327. 10.1016/j.anndiagpath.2008.02.008.PubMedCrossRef

Alkhabuli JO, High AS: Significance of eosinophil counting in tumor associated tissue eosinophilia (TATE). Oral Oncol. 2006, 42: 849-850. 10.1016/j.oraloncology.2005.11.023.PubMedCrossRef

Alrawi SJ, Tan D, Stoler DL, Dayton M, Anderson GR, Mojica P, Douglas W, Hicks W, Rigual N, Loree T: Tissue eosinophilic infiltration: a useful marker for assessing stromal invasion, survival and locoregional recurrence in head and neck squamous neoplasia. Cancer J. 2005, 11: 217-225. 10.1097/00130404-200505000-00008.PubMedCrossRef

Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT: Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology. 2002, 41: 152-157.PubMedCrossRef

Horiuchi K, Mishima K, Ohsawa M, Sugimura M, Aozasa K: Prognostic factors for well-differentiated squamous cell carcinoma in the oral cavity with emphasis on immunohistochemical evaluation. J Surg Oncol. 1993, 53: 92-96. 10.1002/jso.2930530209.PubMedCrossRef

Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999, 59: 991-994.PubMed

Mohammed SI, Coffman K, Glickman NW, Hayek MG, Waters DJ, Schlittler D, DeNicola DB, Knapp DW: Prostaglandin E2 concentrations in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids. 2001, 64: 1-4. 10.1054/plef.2000.0231.PubMedCrossRef

10.

Pannone G, Bufo P, Caiaffa MF, Serpico R, Lanza A, Lo Muzio L, Rubini C, Staibano S, Petruzzi M, De Benedictis M: Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int J Immunopathol Pharmacol. 2004, 17: 273-282.PubMed

11.

Renkonen J, Wolff H, Paavonen T: Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch. 2002, 440: 594-597. 10.1007/s00428-002-0616-y.PubMedCrossRef

12.

Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D, Nagumo M: Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis. 2004, 21: 737-745.PubMedCrossRef

13.

Mestre JR, Chan G, Zhang F, Yang EK, Sacks PG, Boyle JO, Shah JP, Edelstein D, Subbaramaiah K, Dannenberg AJ: Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann N Y Acad Sci. 1999, 889: 62-71. 10.1111/j.1749-6632.1999.tb08724.x.PubMedCrossRef

14.

Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A: The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res. 2003, 9: 1885-1897.PubMed

15.

Sumitani K, Kamijo R, Toyoshima T, Nakanishi Y, Takizawa K, Hatori M, Nagumo M: Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med. 2001, 30: 41-47. 10.1034/j.1600-0714.2001.300107.x.PubMedCrossRef

16.

Fujishima H, Fukagawa K, Okada N, Takano Y, Tsubota K, Hirai H, Nagata K, Matsumoto K, Saito H: Prostaglandin D2 induces chemotaxis in eosinophils via its receptor CRTH2 and eosinophils may cause severe ocular inflammation in patients with allergic conjunctivitis. Cornea. 2005, 24: S66-S70. 10.1097/01.ico.0000178733.42921.4c.PubMedCrossRef

17.

Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K: Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001, 193: 255-261. 10.1084/jem.193.2.255.PubMedPubMedCentralCrossRef

18.

Monneret G, Gravel S, Diamond M, Rokach J, Powell WS: Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood. 2001, 98: 1942-1948. 10.1182/blood.V98.6.1942.PubMedCrossRef

19.

Davoine F, Ferland C, Chakir J, Lee JE, Adamko DJ, Moqbel R, Laviolette M: Interleukin-12 inhibits eosinophil degranulation and migration but does not promote eosinophil apoptosis. Int Arch Allergy Immunol. 2006, 140: 277-284. 10.1159/000093705.PubMedCrossRef

20.

Ferland C, Guilbert M, Davoine F, Flamand N, Chakir J, Laviolette M: Eotaxin promotes eosinophil transmigration via the activation of the plasminogen-plasmin system. J Leukoc Biol. 2001, 69: 772-778.PubMed

21.

Aritake K, Kado Y, Inoue T, Miyano M, Urade Y: Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem. 2006, 281: 15277-15286. 10.1074/jbc.M506431200.PubMedCrossRef

22.

Schuligoi R, Sedej M, Waldhoer M, Vukoja A, Sturm EM, Lippe IT, Peskar BA, Heinemann A: Prostaglandin H2 induces the migration of human eosinophils through the chemoattractant receptor homologous molecule of Th2 cells, CRTH2. J Leukoc Biol. 2009, 85: 136-145.PubMedCrossRef

23.

Adamko DJ, Wu Y, Gleich GJ, Lacy P, Moqbel R: The induction of eosinophil peroxidase release: improved methods of measurement and stimulation. J Immunol Methods. 2004, 291: 101-108. 10.1016/j.jim.2004.05.003.PubMedCrossRef

24.

Pereira MC, Oliveira DT, Kowalski LP: The role of eosinophils and eosinophil cationic protein in oral cancer: a review. Arch Oral Biol. 2011, 56: 353-358. 10.1016/j.archoralbio.2010.10.015.PubMedCrossRef

25.

Hoshikawa H, Goto R, Mori T, Mitani T, Mori N: Expression of prostaglandin E2 receptors in oral squamous cell carcinomas and growth inhibitory effects of an EP3 selective antagonist, ONO-AE3-240. Int J Oncol. 2009, 34: 847-852.PubMedCrossRef

26.

Husvik C, Khuu C, Bryne M, Halstensen TS: PGE2 production in oral cancer cell lines is COX-2-dependent. J Dent Res. 2009, 88: 164-169. 10.1177/0022034508329519.PubMedCrossRef

27.

van Haelst Pisani C, Kovach JS, Kita H, Leiferman KM, Gleich GJ, Silver JE, Dennin R, Abrams JS: Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood. 1991, 78: 1538-1544.PubMed

28.

Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu K, Parmiani G: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer. 1993, 54: 8-15. 10.1002/ijc.2910540103.PubMedCrossRef

29.

Bosse M, Audette M, Ferland C, Pelletier G, Chu HW, Dakhama A, Lavigne S, Boulet LP, Laviolette M: Gene expression of interleukin-2 in purified human peripheral blood eosinophils. Immunology. 1996, 87: 149-154.PubMedPubMedCentral

30.

Levi-Schaffer F, Barkans J, Newman TM, Ying S, Wakelin M, Hohenstein R, Barak V, Lacy P, Kay AB, Moqbel R: Identification of interleukin-2 in human peripheral blood eosinophils. Immunology. 1996, 87: 155-161.PubMedPubMedCentral

31.

Conesa A, Tassinari P, Aldrey O, Taylor P, Bianco NE, De Sanctis JB: Interleukin-2 induces peroxide production by primed normodense eosinophils of patients with asthma. Allergy Asthma Proc. 2003, 24: 27-33.PubMed

32.

Valerius T, Repp R, Kalden JR, Platzer E: Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol. 1990, 145: 2950-2958.PubMed

33.

Huland E, Huland H: Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol. 1992, 118: 463-467. 10.1007/BF01629431.PubMedCrossRef

34.

Moroni M, Porta C, De Amici M, Quaglini S, Cattabiani MA, Buzio C: Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients. Haematologica. 2000, 85: 298-303.PubMed

35.

Kubo H, Loegering DA, Adolphson CR, Gleich GJ: Cytotoxic properties of eosinophil granule major basic protein for tumor cells. Int Arch Allergy Immunol. 1999, 118: 426-428. 10.1159/000024154.PubMedCrossRef

36.

Neves JS, Perez SA, Spencer LA, Melo RC, Reynolds L, Ghiran I, Mahmudi-Azer S, Odemuyiwa SO, Dvorak AM, Moqbel R, Weller PF: Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Natl Acad Sci U S A. 2008, 105: 18478-18483. 10.1073/pnas.0804547105.PubMedPubMedCentralCrossRef

37.

Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, Kay AB, Rothenberg ME: Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008, 38: 709-750. 10.1111/j.1365-2222.2008.02958.x.PubMedCrossRef

Title: Eosinophils in human oral squamous carcinoma; role of prostaglandin D2
Authors: Francis Davoine
Adrian Sim
Charlie Tang
Sibina Fisher
Caroline Ethier
Lakshmi Puttagunta
Yingqi Wu
W Tim McGaw
Donald Yu
Lisa Cameron
Darryl J Adamko
Redwan Moqbel
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Inflammation / Issue 1/2013
Electronic ISSN: 1476-9255
DOI: https://doi.org/10.1186/1476-9255-10-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Eosinophils in human oral squamous carcinoma; role of prostaglandin D2

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

MicroRNA-146 inhibits pro-inflammatory cytokine secretion through IL-1 receptor-associated kinase 1 in human gingival fibroblasts

Role of hypoxia inducible factor-1 in keratinocyte inflammatory response and neutrophil recruitment

Transient expansion of activated CD8+ T cells characterizes tuberculosis-associated immune reconstitution inflammatory syndrome in patients with HIV: a case control study

Oleic acid inhibits lung Na/K-ATPase in mice and induces injury with lipid body formation in leukocytes and eicosanoid production

Differential expression of prolyl hydroxylase 1 in patients with ulcerative colitis versus patients with Crohn’s disease/infectious colitis and healthy controls

MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page